Advertisement

Is Novocure a Buy?

Is Novocure a Buy?

On April 13, Novocure (NASDAQ: NVCR) stock jumped after the company received a green light to accelerate a pivotal phase 3 study. The investigation involves its medical device, Optune, to treat advanced-stage non-small-cell lung cancer (NSCLC). Optune is a portable device that applies small alternating electric currents to cancer cells in the patients' bodies, disrupting their replication process and causing cell death.